MedPath

Flutemetamol

Generic Name
Flutemetamol
Drug Type
Small Molecule
Chemical Formula
C14H11FN2OS
CAS Number
637003-10-2
Unique Ingredient Identifier
0F3M7032P5
Background

Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

Clinical Trials
Related News

The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition

Phase 2
Active, not recruiting
Conditions
Cognitive Impairment
Carotid Artery Plaque
Inflammation
Interventions
First Posted Date
2017-03-01
Last Posted Date
2024-01-11
Lead Sponsor
Scott Mcnally
Target Recruit Count
45
Registration Number
NCT03068442
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

🇺🇸

George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States

Comparison of PET Amyloid Imaging in Japanese and Western Subjects

Phase 2
Completed
Conditions
Mild Cognitive Impairment
Healthy
Alzheimer's Disease
Interventions
First Posted Date
2016-06-24
Last Posted Date
2017-06-05
Lead Sponsor
GE Healthcare
Target Recruit Count
70
Registration Number
NCT02813070

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3
Terminated
Conditions
Mild Cognitive Impairment
Alzheimer's Disease
Dementia
Interventions
First Posted Date
2015-02-03
Last Posted Date
2020-01-21
Lead Sponsor
University of Zurich
Target Recruit Count
11
Registration Number
NCT02353949
Locations
🇨🇭

University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy, Schlieren, Zurich, Switzerland

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

Phase 3
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-12-23
Last Posted Date
2013-07-02
Lead Sponsor
GE Healthcare
Target Recruit Count
218
Registration Number
NCT01265394
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

Phase 3
Completed
Conditions
Brain Fibrillarab Levels
Interventions
First Posted Date
2010-07-20
Last Posted Date
2013-12-04
Lead Sponsor
GE Healthcare
Target Recruit Count
203
Registration Number
NCT01165554
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Phase 3
Completed
Conditions
Normal Pressure Hydrocephalus
Interventions
First Posted Date
2010-01-21
Last Posted Date
2012-06-11
Lead Sponsor
GE Healthcare
Target Recruit Count
7
Registration Number
NCT01053312
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Phase 3
Completed
Conditions
Mild Cognitive Impairment
Alzheimer's Disease
Interventions
First Posted Date
2009-12-09
Last Posted Date
2014-09-11
Lead Sponsor
GE Healthcare
Target Recruit Count
365
Registration Number
NCT01028053
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy